These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25080432)

  • 21. [Intensive blood glucose reduction: yes or no?].
    Bischoff A
    MMW Fortschr Med; 2015 Mar; 157(4):18-9. PubMed ID: 25743962
    [No Abstract]   [Full Text] [Related]  

  • 22. Metformin as an adjunctive therapy for NIDDM.
    Waterman PE
    Nurse Pract; 1996 Apr; 21(4):150-2. PubMed ID: 8801483
    [No Abstract]   [Full Text] [Related]  

  • 23. A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes.
    Goldenberg RM; Assimakopoulos P; Gilbert JD; Gottesman IS; Yale JF
    Diabetes Obes Metab; 2018 Sep; 20(9):2064-2074. PubMed ID: 29707875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).
    Aroda VR; Bailey TS; Cariou B; Kumar S; Leiter LA; Raskin P; Zacho J; Andersen TH; Philis-Tsimikas A
    Diabetes Obes Metab; 2016 Jul; 18(7):663-70. PubMed ID: 26990378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.
    Wang MM; Lin S; Chen YM; Shu J; Lu HY; Zhang YJ; Xie RY; Zeng LY; Mu PW
    Diabetes Res Clin Pract; 2015 Jun; 108(3):e67-70. PubMed ID: 25841300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
    Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
    [No Abstract]   [Full Text] [Related]  

  • 27. [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
    Yan L; Wang S; Chen P; Chen C; Shao Z; Xu X; Huang Q
    Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):307-12. PubMed ID: 26268058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
    N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.
    Karl D; Zhou R; Vlajnic A; Riddle M
    Diabet Med; 2012 Jul; 29(7):933-6. PubMed ID: 22413808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on perioperative management of diabetes.
    Jacober SJ; Sowers JR
    Arch Intern Med; 1999 Nov; 159(20):2405-11. PubMed ID: 10665888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Critical questions on diabetes therapy and their sequelae. HbA1c: may it be more than 7 after all?].
    Aumiller J
    MMW Fortschr Med; 2009 Oct; 151(42):14-6. PubMed ID: 19938773
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes.
    Pistrosch F; Köhler C; Schaper F; Landgraf W; Forst T; Hanefeld M
    Acta Diabetol; 2013 Aug; 50(4):587-95. PubMed ID: 23430192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not Available].
    Zulewski H
    Ther Umsch; 2017; 74(8):411-416. PubMed ID: 29461143
    [No Abstract]   [Full Text] [Related]  

  • 34. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
    Billings LK; Doshi A; Gouet D; Oviedo A; Rodbard HW; Tentolouris N; Grøn R; Halladin N; Jodar E
    Diabetes Care; 2018 May; 41(5):1009-1016. PubMed ID: 29483185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk.
    Wareham NJ; Pfister R
    Nat Rev Cardiol; 2010 Jul; 7(7):367-8. PubMed ID: 20577298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peri-operative management of diabetes.
    Lavies NG; May J
    Anaesthesia; 2007 Jun; 62(6):631; author reply 632. PubMed ID: 17506748
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of diabetes mellitus: implications of the use of oral agents.
    Rao SV; Bethel MA; Feinglos MN
    Am Heart J; 1999 Nov; 138(5 Pt 1):S334-7. PubMed ID: 10539794
    [No Abstract]   [Full Text] [Related]  

  • 39. An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study.
    Blackberry ID; Furler JS; Ginnivan LE; Manski-Nankervis JA; Jenkins A; Cohen N; Best JD; Young D; Liew D; Ward G; O'Neal DN
    Diabetes Res Clin Pract; 2014 Nov; 106(2):247-55. PubMed ID: 25271117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
    Khunti K; Caputo S; Damci T; Dzida GJ; Ji Q; Kaiser M; Karnieli E; Liebl A; Ligthelm RJ; Nazeri A; Orozco-Beltran D; Pan C; Ross SA; Svendsen AL; Vora J; Yale JF; Meneghini LF;
    Diabetes Obes Metab; 2012 Dec; 14(12):1129-36. PubMed ID: 22830956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.